FGFR2 and breast carcinoma: Multiple FGFR2 dysregulations have also been detected in breast cancer [93], lung cancer [94,95] (both adenocarcinoma and squamous cell carcinoma), and intrahepatic cholangiocarcinoma, in which fusions of FGFR2 constitute an oncogenic potential for this aberration [96].